Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALM1 | P0DP23 | 2/20 | 0.62 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.60 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30101936 | 1.00 | CALM1 (0.62) | CALM1TAAR1HDAC1HDAC3HDAC6 | |
| SCHEMBL26919 | 0.98 | HDAC1 (0.62) | CALM1TAAR1HDAC1HDAC3HDAC6 | |
| Hydrogen Sulfide SCHEMBL28114002 | 0.97 | HDAC1 (0.61) | CALM1TAAR1HDAC1HDAC3HDAC6 | |
| SCHEMBL79785 | 0.95 | CALM1 (0.64) | CALM1TAAR1HDAC1HDAC3HDAC6 | |
| SCHEMBL28867370 | 0.94 | CALM1 (0.60) | CALM1TAAR1HDAC1HDAC3HDAC6 | |
| Piperazine SCHEMBL28067428 | 0.91 | HDAC1 (0.56) | CALM1TAAR1HDAC1HDAC3HDAC6 | |
| Acetone SCHEMBL28206012 | 0.91 | HDAC1 (0.63) | CALM1TAAR1HDAC1HDAC3HDAC6 | |
| Acetonitrile SCHEMBL28510985 | 0.89 | HDAC1 (0.54) | CALM1TAAR1HDAC1HDAC3HDAC6 | |
| SCHEMBL3108886 | 0.88 | HDAC1 (0.51) | CALM1TAAR1HDAC1HDAC3HDAC6 | |
| SCHEMBL29644736 | 0.87 | TAAR1 (0.67) | CALM1TAAR1HDAC1HDAC3HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11325937-B2 | Glycoside compound and preparation method therefor, composition, application, and intermediate | SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED (CN) | 2022-05-10 | — | — | US | disclosed |
| WO-2021139621-A1 | METHOD FOR PREPARING GLYCOSIDE COMPOUND | 上海和黄药业有限公司 | 2021-07-15 | — | — | WO | disclosed |
| EP-3819303-A1 | GLYCOSIDE COMPOUND AND PREPARATION METHOD THEREFOR, COMPOSITION, APPLICATION, AND INTERMEDIATE | Shanghai Hutchison Pharmaceuticals Limited (CN) | 2021-05-12 | — | — | EP | disclosed |
| US-20210115082-A1 | GLYCOSIDE COMPOUND AND PREPARATION METHOD THEREFOR, COMPOSITION, APPLICATION, AND INTERMEDIATE | SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED (CN) | 2021-04-22 | — | — | US | disclosed |
| US-9386767-B2 | Derivatives of dillapiol and related monolignans and use thereof | UNIVERSITY OF OTTAWA (CA) | 2016-07-12 | — | — | US | disclosed |
| US-9386767-B2 | Derivatives of dillapiol and related monolignans and use thereof | UNIVERSITY OF OTTAWA (CA) | 2016-07-12 | — | — | US | disclosed |
| US-20130012477-A1 | DERIVATIVES OF DILLAPIOL AND RELATED MONOLIGNANS AND USE THEREOF | HER MAJESTY THE QUEEN IN RIGHT OF CANADA AS REPRESENTED BY THE MINISTER OF HEALTH (CA) | 2013-01-10 | — | — | US | disclosed |
| US-20130012477-A1 | DERIVATIVES OF DILLAPIOL AND RELATED MONOLIGNANS AND USE THEREOF | HER MAJESTY THE QUEEN IN RIGHT OF CANADA AS REPRESENTED BY THE MINISTER OF HEALTH (CA) | 2013-01-10 | — | — | US | disclosed |
| CN-101897986-A | The box privy deodorizing method of liquid deodorant and box privy | SHIZUOKA PREFECTURAL UNIVERSIT | 2010-12-01 | — | — | CN | disclosed |
| WO-2006103527-A1 | AROMATIC SUBSTITUTED PENTADIENOIC ACID AMIDE FOR COMBINATION WITH ANTI-INFECTIVE DRUGS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-10-05 | — | — | WO | disclosed |
| CN-1274839-C | Process for the preparation of enantiomerically enriched esters and alcohols | DSM NV (NL) | 2006-09-13 | — | — | CN | disclosed |
| CN-1430677-A | Process for the preparation of enantiomerically enriched esters and alcohols | DSM NV (NL) | 2003-07-16 | — | — | CN | disclosed |
| CN-1365962-A | Process for preparing piperonyl propionaldehyde | GELIN PERFUME CHEMISTRY CO LTD (CN) | 2002-08-28 | — | — | CN | disclosed |
| US-5243076-A | Adrenergic stimulant intermediates | GLAXO GROUP LTD. | 1993-09-07 | — | — | US | disclosed |
| US-5225445-A | Respiratory system disorders | GLAXO GROUP LTD. | 1993-07-06 | — | — | US | disclosed |
| US-5126375-A | Asthma, chronic bronchitis | GLAXO GROUP LTD. (GB) | 1992-06-30 | — | — | US | disclosed |
| US-5091422-A | Treating inflammatory or allergic skin disease, lowering gastric acidity | GLAXO GROUP LIMITED (GB) | 1992-02-25 | — | — | US | disclosed |
| US-4992474-A | Adrenergic stimulants | GLAXO GROUP LTD. (GB) | 1991-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325937-B2 | Glycoside compound and preparation method therefor, composition, application, and intermediate | VEGFA, FLT4, FLT1 | CALM1 3278/4885TAAR1 4836/4885HDAC1 4220/4885 |
| US-20130012477-A1 | DERIVATIVES OF DILLAPIOL AND RELATED MONOLIGNANS AND USE THEREOF | CYP3A43, CYP3A4, CYP4A22 | CALM1 859/4885TAAR1 3430/4885HDAC1 330/4885 |
| US-20210115082-A1 | GLYCOSIDE COMPOUND AND PREPARATION METHOD THEREFOR, COMPOSITION, APPLICATION, AND INTERMEDIATE | VEGFA, FLT4, FLT1 | CALM1 3278/4885TAAR1 4836/4885HDAC1 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.